VFA
STRO icon

Values First Advisors’s Sutro Biopharma STRO Stock Holding History

Values First Advisors’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-394
Closed -$18.2K – 321
2023
Q1 		$18.2K Buy
+394
New +$25K 0.01% 216

Other funds holding STRO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Values First Advisors's STRO Position: Q2 2023 in Review

Values First Advisors sold out of Sutro Biopharma (STRO) in Q2 2023, closing a stake of 394 shares — an estimated $18.2K sold.

Values First Advisors first reported a position in STRO in Q1 2023 and held it in 1 quarter. The position peaked at $18.2K in Q1 2023. 120 funds tracked by Wall St. Rank hold STRO as of Q2 2023.

  • Values First Advisors reported no remaining Sutro Biopharma position as of Q2 2023 after selling out during the quarter.
  • Values First Advisors sold 394 Sutro Biopharma shares in Q2 2023, an estimated $18.2K.
  • Values First Advisors first reported a position in Sutro Biopharma in Q1 2023 and held it in 1 quarter.
  • Values First Advisors's Sutro Biopharma position peaked at $18.2K in Q1 2023.
  • 120 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2023.

Based on Values First Advisors's 13F filing for Q2 2023, filed 2 Aug 2023.